Influenza Vaccines Market – Increasing demand, leading to improved pandemic preparedness is expected to incredible growth of the market
Influenza is commonly referred as flu, a contagious respiratory illness that is caused by influenza virus. The virus can cause mild to severe illness, resulting in serious outcomes such as hospitalization or death. Geriatric population, pregnant women, and people with chronic health conditions are at high risk of serious flu complications. Influenza virus is responsible for seasonal epidemic events and are classified into two types of influenza virus, including A and B. The influenza vaccines market is expected to gain significant traction over the forecast period, as number of manufacturers are increasing the production capacity of vaccines for use in the U.S. market for the 2017–2018 influenza season using the innovative technologies such as egg-based, cell-based, and recombinant technologies.
Key Players Profiled in the U.S. Influenza Vaccines Market Report are as follows: Sanofi Pasteur, Seqirus Vaccines Ltd., GlaxoSmithKline Plc., and Medimmune.
Request Sample Copy of U.S. Influenza Vaccines Report @
https://www.coherentmarketinsights.com/insight/request-sample/1127
Manufacturers are focusing on the development of vaccine by using innovative technologies such as adopting novel recombinant and cell-based vaccine production technologies to increase their supply capacity. For instance, Protein Science Corporation received the U.S. FDA approval for Flubok Trivalent Vaccine for use in the U.S. market in 2013. Flubok is the only influenza vaccine produced using recombinant technology, which offers advantages such as timely and fast vaccine production as the technology is not dependent on egg supply for vaccine production and is safe for individuals with egg-related allergies.
Moreover, in 2016, Seqirus received the U.S. FDA approval for Flucelvax quadrivalent, indicated for people aged 4 years and above. Flucevax is a four strain, inactivated seasonal influenza vaccine, which is produced using cell culture technology at the Holly Springs Facility in the U.S. The vaccine was recommended by the World Health Organization and the Food and Drug Administration for the 2016 influenza season, in order to help protect against two influenza virus strains, which include A strains and B strains.
The U.S. influenza vaccines market is expected to gain significant traction, owing to easy availability of different vaccines, which include adjuvanted inactivated vaccines, live-attenuated vaccines, seasonal influenza vaccines, and pandemic influenza vaccines. The transition from trivalent to quadrivalent vaccine formulations due to extensive research and development, to offer better protection against flu strains is a major factor which is expected to augment growth of the U.S. influenza vaccine market over the forecast period.
For instance, in November 2019, Sanofi received the U.S. Food and Drug Administration (FDA) approval for a supplemental Biologics License Application for Fluzone High-Dose Quadrivalent (Influenza Vaccine) for use in adults 65 years of age and older. Earlier, in 2009, Fluzone High-Dose (Influenza Vaccine) was approved by the U.S. FDA. This approval has enabled the Sanofi to sell and distribute the quadrivalent influenza vaccines in the U.S. According to the company, the new vaccine will be available for immunization schedule/efforts during the 2020-2021 influenza season.
Enquiry Before Buying This Report:
https://www.coherentmarketinsights.com/insight/talk-to-analyst/1127
able of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Vaccine Type
- Market Snippet, By Virus Type
- Market Snippet, By Age Group
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- Epidemiology
- PEST Analysis
- Key Highlights
- Recommendations for Nasal Spray Vaccines
- Influenza Vaccines Production Technologies
- Influenza Vaccines Approved in U.S., 2017-18 Influenza Season
- Influenza Vaccine Price List
- Supply Capacity of Major Manufacturers
- Market Dynamics
- U.S. Influenza Vaccines Market, By Vaccine Type, 2016–2027, (US$ Billion)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017–2027
- Segment Trends
- Trivalent Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Billion)
- Quadrivalent Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Billion)
- Introduction
- U.S. Influenza Vaccines Market, By Virus Type, 2016–2027, (US$ Billion)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017–2027
- Segment Trends
- Influenza Virus Type A
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Billion)
- Influenza Virus Type B
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Billion)
- Introduction
- U.S. Influenza Vaccines Market, By Age Group, 2016–2027, (US$ Billion)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017–2027
- Segment Trends
- Pediatrics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Billion)
- Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Billion)
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis (3×3 Matrix)
- Company Profiles
- Sanofi Pasteur*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Seqirus Vaccines Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- GlaxoSmithKline Plc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Medimmune
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Analyst Views
- Sanofi Pasteur*
- Section
- References
- Research Methodology
- About us and Sales Contact
Why You Should Buy This Report?
• To gain an in-depth understanding of U.S. Influenza Vaccines market globally
• To identify the on-going trends and anticipated growth in the next nine years
• To help industry consultants, U.S. Influenza Vaccines market other stakeholders align their market-centric strategies
• To obtain research-based business decisions and add weight to presentations and marketing strategies
• To gain competitive knowledge of leading market players
Request for Customization:
https://www.coherentmarketinsights.com/insight/request-customization/1127
The report answers questions such as:
• What is the market size and forecast of the U.S. Influenza Vaccines market?
• What are the inhibiting factors and impact of COVID-19 shaping the U.S. Influenza Vaccines market during the forecast period?
• Which are the products/segments/applications/areas to invest in over the forecast period in the U.S. Influenza Vaccines market?
• What is the competitive strategic window for opportunities in the U.S. Influenza Vaccines market?
• What are the technology trends and regulatory frameworks in the U.S. Influenza Vaccines market?
• What are the modes and strategic moves considered suitable for entering the U.S. Influenza Vaccines market?
Note: Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.
Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
Contact us:
Mr. Shah
Senior Client Partner – Business Development
sales@coherentmarketinsights.com
www.coherentmarketinsights.com
Editor Details
-
Company:
- CDN Newswire
